Bohemine

Research use only, not for human use.

Bohemine is a cyclin-dependent kinase inhibitor.

Bohemine is a cyclin-dependent kinase inhibitor.

Bohemine (0-30 μM; 72 hours; ME-750 cells) treatment inhibits cell growth. Addition of Bohemine at concentrations in the range of 1-10 μM results in a short-term arrest of growth and of monoclonal antibody production. The short-term suppression of cell functions is followed by a significant temporary increase of specific growth rate and of specific production rate.Hybridoma cells are retarded both at the G1/S boundary and at the G2/M boundary, depending on Bohemine (0-30 μM) concentration.T-lymphoblastic cell line CEM is treated by Bohemine, five proteins are found to be downregulated, namely α-enolase, triosephosphate isomerase, initiation factor 5A, and α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins play significant roles in glycolysis, proteosynthesis, and in cytoskeleton rearrangement.Bohemine inhibits growth of human tumor cell lines with an IC50 of 27 μM. Cell Viability Assay Cell Line:Mouse hybridoma ME-750 cells Concentration:0 μM, 1 μM, 3 μM, 10 μM and 30 μM Incubation Time:72 hours Result:At 10 μM and 30 μM concentrations, the viable cell count was significantly lower with respect to control, i.e., 77% and 48%, respectively.

Bohemine (50 mg/kg; intravenous injection; BALB/c mice) treatment shows Cmax is 72,308 nM, observed clearance is 0.23 L/h and T1/2 is 1.39 h. Animal Model:BALB/c mice bearing the colon 26 murine tumorDosage:50 mg/kg Administration:Intravenous injection (Pharmacokinetic Analysis) Result:Cmax is 72,308 nM, observed clearance is 0.23 L/h and T1/2 is 1.39 h.

Bohemine

Angiogenesis

CDK

CDK

——

——

189232-42-6

340.42

C18H24N6O

>98% (HPLC)

DMSO: 10 mM

CC(N1C=NC2=C1N=C(NCCCO)N=C2NCC3=CC=CC=C3)C

3-((6-(benzylamino)-9-isopropyl-9H-purin-2-yl)amino)propan-1-ol

(-20℃)

With Ice Pack

≥ 2 years